Treatment options for relapsed and refractory multiple myeloma.
about
From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myelomaEuropean perspective on multiple myeloma treatment strategies in 2014Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomibDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingIntegrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.European perspective on multiple myeloma treatment strategies: update following recent congressesNaltrindole inhibits human multiple myeloma cell proliferation in vitro and in a murine xenograft model in vivoIbrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma.B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple MyelomaGlobal cellular response to chemotherapy-induced apoptosis.Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myelomaPomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyFrom myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.Proteasome inhibitors in multiple myeloma: 10 years later.MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.Evolving therapeutic paradigms for multiple myeloma: back to the future.Emerging pathways as individualized therapeutic target of multiple myeloma.Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma.The emerging role of carfilzomib combination therapy in the management of multiple myeloma.Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.Overcoming bortezomib resistance in multiple myeloma.The future of proteasome inhibitors in relapsed/refractory multiple myeloma.Treatment-related symptom management in patients with multiple myeloma: a review.Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity.TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.Treatment of MM: Upcoming Novel Therapies.A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
P2860
Q26862828-46CACEB3-4421-4555-991D-415A9FBCE56FQ27005966-7ADCC388-7910-4662-8D47-67E1D1625EACQ27014143-F8BD1DDC-CC17-4106-8F8C-5CD110379A91Q27692033-DFE3ED7A-6B2D-450C-94FD-279152DC69DBQ28082335-DC6E9088-B78A-4A69-9501-195B8C1E3AC3Q33409681-C333628E-6189-459D-A436-83D0EE962E6AQ33423168-A5A5238B-9396-4D71-A773-B4C1F86C2DBAQ33627312-A5CE2730-EE09-4E5F-92DD-F1B9F85DDF28Q34798095-F32A97A1-7F18-4480-9272-458A65A48529Q35678607-23DC5043-3FE1-45D9-899F-995587C94126Q35989943-12533927-0E91-4D10-BD9C-7B577B094E04Q36105355-8D727949-D5DD-4748-BAC9-230D6360EB71Q36183770-EC4485F3-A1F2-4CDA-9583-37299DBF5B88Q36527905-0ACD2799-4E17-4065-A99E-2745FE81F311Q36778126-AD688595-A8E5-493B-B733-2A17A7F689F4Q37016562-6789AE56-56D5-4236-B59A-2B44951DB2E6Q37146291-390B4327-0F89-42B9-8BA3-C5A4B49CC525Q37210703-C0CB3504-9D34-4789-BCFA-AE42A68E5CA7Q37255788-AF4BBCB6-FFD7-48B6-BE34-E548CF702BE5Q37557639-196005D6-C467-4B44-8DEC-95D7D90A8C91Q37655019-360E999D-E55A-467F-9DBF-C772F2581B58Q37853733-D40C5F31-5D88-4851-8B1B-850B70839512Q37946246-738F1BB9-E052-4077-9858-C7805AA5C99FQ38014395-F1730D3A-1B6A-429D-866F-187E91E6F4F3Q38026589-D0D9E933-263E-4EE7-B050-912EB080B0E7Q38033590-9154083A-D8EB-42A9-A35A-BED840241E0CQ38112176-BE6E3175-7F67-4B52-9196-04CF2EFD1D7DQ38154927-96FA0032-FEB6-4925-B1CB-F3B2A9A496BBQ38187476-CF5B03D9-9975-4244-BFBD-C9766FE36610Q38202977-7B3BAC78-2C58-4A20-905E-C2B77E9777ABQ38238610-3273E5BB-AE94-4958-8038-027DE6DB47E2Q38246060-14F43F5B-965B-459A-920A-FB83FDFD7124Q38342281-350B3DE8-79EA-447C-BA11-EED7D4633756Q38601582-B7BBEA97-E7E9-4A8F-9A82-8C3B533BCF81Q38756800-632145D1-8728-48E4-8DDB-FC0192F01113Q38800369-242B6356-616F-4663-AD8C-BB898B565DE5Q38805723-A45DEB2B-5A8B-4515-9C04-A3CE930DB14FQ38807562-58E7AB69-C083-4A06-B7CA-B99CF8640701Q38815402-78BB6A91-9212-4A7A-8B00-F1EAE64A696BQ38954303-5D525628-910A-4B7A-942F-538CB231E967
P2860
Treatment options for relapsed and refractory multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment options for relapsed and refractory multiple myeloma.
@en
Treatment options for relapsed and refractory multiple myeloma.
@nl
type
label
Treatment options for relapsed and refractory multiple myeloma.
@en
Treatment options for relapsed and refractory multiple myeloma.
@nl
prefLabel
Treatment options for relapsed and refractory multiple myeloma.
@en
Treatment options for relapsed and refractory multiple myeloma.
@nl
P1476
Treatment options for relapsed and refractory multiple myeloma.
@en
P2093
Constantine S Mitsiades
P304
P356
10.1158/1078-0432.CCR-10-1805
P407
P577
2011-03-01T00:00:00Z